Management of malignancy-associated pleural effusion: current and future treatment strategies.

Evaldo Marchi, Lisete R Teixeira, Francisco S Vargas
{"title":"Management of malignancy-associated pleural effusion: current and future treatment strategies.","authors":"Evaldo Marchi,&nbsp;Lisete R Teixeira,&nbsp;Francisco S Vargas","doi":"10.1007/BF03256654","DOIUrl":null,"url":null,"abstract":"<p><p>Management of recurrent malignant pleural effusion, a common complication of malignancy, poses a challenge to clinicians. Although almost one century has elapsed since the introduction of the pleurodesis procedure, the ideal approach and best agent are still to be defined. Optimally, pleurodesis should be done at the bedside with a minimally invasive procedure, and suitable agents to achieve pleural symphysis should be inexpensive, available worldwide and free of adverse effects. To date, no substance completely fulfills these requirements. Silver nitrate should be considered for pleurodesis because of its low cost and ease of handling. Although talc has been used most frequently to induce pleurodesis, reports of death due to acute respiratory failure have raised concerns about the safety of this agent. Tetracycline, an effective alternative used in the past, is no longer commercially available. This agent has been substituted with derivatives of tetracycline, such as minocycline and doxycycline with success rates similar to those with tetracycline. Several antineoplastic agents have been injected into the pleural space with the aim of producing pleural symphysis, the most representative of this group being bleomycin. Recent knowledge of the molecular mechanisms involved in pleural inflammation has brought into focus new substances, such as transforming growth factor beta and vascular endothelial growth factor, which may be used as pleurodesis agents in the future. Nevertheless, more studies are necessary to better define the potential of these substances in the induction of pleural symphysis.Ideally, a sclerosing agent should be cost-effective, available worldwide and easily administered. Talc will probably stand as the preferred agent to be used for pleurodesis in malignant pleural effusion because of its efficacy, easy manipulation and handling. However, further investigation is necessary to minimize adverse effects related to talc.</p>","PeriodicalId":86933,"journal":{"name":"American journal of respiratory medicine : drugs, devices, and other interventions","volume":"2 3","pages":"261-73"},"PeriodicalIF":0.0000,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF03256654","citationCount":"24","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of respiratory medicine : drugs, devices, and other interventions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF03256654","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 24

Abstract

Management of recurrent malignant pleural effusion, a common complication of malignancy, poses a challenge to clinicians. Although almost one century has elapsed since the introduction of the pleurodesis procedure, the ideal approach and best agent are still to be defined. Optimally, pleurodesis should be done at the bedside with a minimally invasive procedure, and suitable agents to achieve pleural symphysis should be inexpensive, available worldwide and free of adverse effects. To date, no substance completely fulfills these requirements. Silver nitrate should be considered for pleurodesis because of its low cost and ease of handling. Although talc has been used most frequently to induce pleurodesis, reports of death due to acute respiratory failure have raised concerns about the safety of this agent. Tetracycline, an effective alternative used in the past, is no longer commercially available. This agent has been substituted with derivatives of tetracycline, such as minocycline and doxycycline with success rates similar to those with tetracycline. Several antineoplastic agents have been injected into the pleural space with the aim of producing pleural symphysis, the most representative of this group being bleomycin. Recent knowledge of the molecular mechanisms involved in pleural inflammation has brought into focus new substances, such as transforming growth factor beta and vascular endothelial growth factor, which may be used as pleurodesis agents in the future. Nevertheless, more studies are necessary to better define the potential of these substances in the induction of pleural symphysis.Ideally, a sclerosing agent should be cost-effective, available worldwide and easily administered. Talc will probably stand as the preferred agent to be used for pleurodesis in malignant pleural effusion because of its efficacy, easy manipulation and handling. However, further investigation is necessary to minimize adverse effects related to talc.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
恶性肿瘤相关胸腔积液的管理:当前和未来的治疗策略。
恶性胸腔积液是恶性肿瘤的一种常见并发症,复发性胸腔积液的处理对临床医生提出了挑战。尽管自引入胸膜固定术以来已经过去了近一个世纪,但理想的入路和最佳的治疗方法仍有待确定。最理想的是,胸膜清释术应在床边进行微创手术,实现胸膜联合的合适药物应价格低廉,在全球范围内可获得,且无不良反应。迄今为止,没有任何物质完全满足这些要求。硝酸银因其成本低且易于处理而应考虑用于胸膜固定术。尽管滑石粉最常用于诱发胸膜穿心术,但因急性呼吸衰竭而死亡的报告引起了人们对该药物安全性的担忧。四环素是过去使用的一种有效的替代药物,现已不再在市场上销售。该药物已被四环素的衍生物取代,如二甲胺四环素和强力霉素,成功率与四环素相似。一些抗肿瘤药物已被注射到胸膜间隙,目的是产生胸膜联合,该组最具代表性的是博来霉素。近年来对胸膜炎症的分子机制的了解使人们关注新的物质,如转化生长因子和血管内皮生长因子,它们可能在未来用作胸膜切除术的药物。然而,需要更多的研究来更好地确定这些物质在诱导胸膜联合中的潜力。理想情况下,一种硬化剂应该具有成本效益,在世界范围内可用并且易于管理。滑石粉因其疗效好、易操作、易处理等优点,有望成为恶性胸腔积液胸膜切除术的首选药物。然而,有必要进一步调查以尽量减少与滑石有关的不良影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The emerging role of leukotriene modifiers in allergic rhinitis. Is there a role for systemic corticosteroids in the management of stable chronic obstructive pulmonary disease? Pseudomonal infections in patients with COPD: epidemiology and management. Treatment of community-acquired lower respiratory tract infections during pregnancy. Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1